DAWN - Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
2024-07-07 06:58:14 ET
Summary
- Today, we circle back to Day One Biopharmaceuticals as the company's stock has dropped some even after its first FDA approval in late April.
- Analysts are optimistic about Day One Biopharmaceuticals, with numerous buy ratings and price targets ranging from $33 to $40 a share. The stock currently trades for less than $14/share.
- Despite the FDA approval, there is still some uncertainty as there are several moving parts to this story. An updated analysis follows in the paragraphs below.
It has been nearly a year since our last look at Day One Biopharmaceuticals, Inc. ( DAWN ). The company has been in the news quite a bit over the past few months. Therefore, it seems a good time to circle back to this oncology focused biopharma concern. An analysis follows below....
Day One Biopharmaceuticals: Still Uncertainty After FDA Approval